Caitlin Raymond: Understanding Risks in Rare Group A Subtypes with Anti-A1 Antibodies in Transfusion Medicine
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at the University of Wisconsin-Madison, shared a post on LinkedIn:
”In transfusion medicine, some risks feel larger than they actually are — not because they’re common, but because the evidence we have is skewed toward worst-case scenarios.
I recently wrote a follow-up blog post on rare group A subtypes with anti-A1 antibodies, prompted by a real case and a conversation with a reference laboratory.
Case reports tell us what can go wrong. Reference labs see what actually does go wrong — and how often.
This post walks through:
- When cold reacting anti-A1 actually becomes dangerous
- Why malignancy-associated cases don’t generalize
- When to choose group O blood for rare group A subtypes
If you’ve ever felt uneasy making decisions where the literature offers warnings but no denominator, this one’s for you.”

Stay updated with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda